A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
Objective
To determine whether treatment with pasritamig+docetaxel prolongs rPFS compared with docetaxel in participants with mCRPC who have progressed on at least one ARPI
